PCSK9 Regulates LDLR Turnover Through Increased Intracellular

Degradation

Genetics PCSK9

PCSK9-Directed Therapies in Development

Alirocumab (SAR236553)Change in LDL-C at 2- and 4-Week Dosing Intervals on

Atorvastatin

Evolocumab (AMG 145) Change in LDL-C at 2- and 4-Week Dosing

Intervals on Statin Therapy

MENDELEvolocumab Monotherapy for Hypercholesterolemia

LAPLACE-TIMI 57 Evolocumab Combined With Statin for

Hypercholesterolemia

StatinsApproximate LDL-C Lowering Efficacy

ENHANCESimvastatin/Ezetimibe in FH

Effect of Alirocumab on LDL-C in Heterozygous FH

RUTHERFORDEffect of Evolocumab on LDL-C in Heterozygous

FH

GAUSSEvolocumab in Statin Intolerance

PCSK9-Directed Therapies in Development

OSLER Extension Study

OSLEREffect of Evolocumab on LDL-C after 52 Weeks

Clinical Utility of PCSK9 Inhibitors

Phase 3 Trials

Use of PCSK9 InhibitorsBased on Evidence or Definitive Outcomes Data?

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)